A spine-zapping implant helped 3 people with a muscle-wasting disease walk better
Three people with a muscle-destroying disease destined to worsen got a little stronger when an implanted device zapped their ...
Amgen Q4 Earnings: Strong Pipeline And Label Expansions Justify Buy Rating
Amgen's Q4 earnings beat expectations, showcasing robust performance for the company's growth strategy. Click here to read ...
FiercePharma20h
With recent launches and more to come, Amgen's biosimilar business is trending up
After recent launches of biosimilar versions of Eylea and Stelara, Amgen projects its biosimilar sales will reach $4 billion ...
BioPharma Dive18h
Amgen obesity drug on hold; Regeneron sets first dividend
The FDA has paused a study of Amgen’s early-stage candidate AMG 513. Elsewhere, Valneva got another approval and a radiopharma developer raised $112 million.
GlobalData on MSN18h
Auxilium’s 3D printer builds medical devices on the International Space Station
Via a collaboration with Nasa, Auxilium has installed a 3D printer on the ISS to test the promise of manufacturing in ...
STAT12h
What happens when a rare disease drug seems to work, but the health care system doesn’t?
Cristina Brennan can hear the clock ticking. At the end of the year, her 12-year-old son Tristan will no longer have free ...
Zacks.com on MSN20h
AMGN's Q4 Earnings Beat, Obesity Candidate Under FDA Clinical Hold
Amgen AMGN reported fourth-quarter 2024 adjusted earnings of $5.31 per share, which beat the Zacks Consensus Estimate of ...